ATE474052T1 - Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose - Google Patents

Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose

Info

Publication number
ATE474052T1
ATE474052T1 AT05020550T AT05020550T ATE474052T1 AT E474052 T1 ATE474052 T1 AT E474052T1 AT 05020550 T AT05020550 T AT 05020550T AT 05020550 T AT05020550 T AT 05020550T AT E474052 T1 ATE474052 T1 AT E474052T1
Authority
AT
Austria
Prior art keywords
recombinant proteins
producing recombinant
apoptosis inhibitors
apoptosis
inhibitors
Prior art date
Application number
AT05020550T
Other languages
English (en)
Inventor
De Goor Jana Van
Robert W Hamilton
Vishva Dixit
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22558684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE474052(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE474052T1 publication Critical patent/ATE474052T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/92—Medium free of human- or animal-derived components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05020550T 1999-09-27 2000-09-25 Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose ATE474052T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15623299P 1999-09-27 1999-09-27

Publications (1)

Publication Number Publication Date
ATE474052T1 true ATE474052T1 (de) 2010-07-15

Family

ID=22558684

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00965426T ATE313634T1 (de) 1999-09-27 2000-09-25 Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose
AT05020550T ATE474052T1 (de) 1999-09-27 2000-09-25 Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00965426T ATE313634T1 (de) 1999-09-27 2000-09-25 Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose

Country Status (12)

Country Link
US (4) US6586206B1 (de)
EP (2) EP1220934B1 (de)
JP (1) JP2003510087A (de)
AT (2) ATE313634T1 (de)
AU (1) AU7614600A (de)
CA (1) CA2384880C (de)
DE (2) DE60044690D1 (de)
DK (2) DK1220934T3 (de)
ES (2) ES2346659T3 (de)
IL (2) IL148512A0 (de)
PT (1) PT1650307E (de)
WO (1) WO2001023592A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2384880C (en) * 1999-09-27 2010-09-21 Genentech, Inc. Methods for making recombinant proteins using apoptosis inhibitors
US7405038B1 (en) * 2000-03-03 2008-07-29 Boyce Thompson Institute For Plant Research, Inc. Stable cell lines resistant to apoptosis and nutrient stress and methods of making same
CN1526011A (zh) * 2001-07-10 2004-09-01 IDECҩ�﹫˾ 抑制凋亡过程及改善细胞性能
KR100454016B1 (ko) * 2002-01-05 2004-10-26 한국과학기술원 항예정사 유전자로 형질전환되고 ｄｈｆｒ 유전자가결핍된 신규한 ｃｈｏ 세포주, 그의 제조 방법 및 상기형질전환된 ｃｈｏ 숙주 세포를 이용한 목적단백질의 생산방법
EP2180045B1 (de) * 2003-10-24 2015-12-23 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Neuartige rekombinante Tierzellen mit hoher Proteinproduktion, Herstellungsverfahren dafür und Verfahren zur Proteinmassenproduktion damit
US7608425B2 (en) * 2004-07-23 2009-10-27 Immunomedics, Inc. Methods for protein expression in mammalian cells in serum-free medium
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
US7537930B2 (en) 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
EP1802646B1 (de) * 2004-07-23 2017-09-06 Immunomedics Inc. Verfahren und zusammensetzungen zur erhöhung von lebensdauer und proteinertrag einer zellkultur
AU2005333513B2 (en) * 2004-07-23 2011-06-02 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
AU2005287278B2 (en) * 2004-09-16 2011-08-04 Sangamo Biosciences, Inc. Compositions and methods for protein production
WO2006071200A2 (en) * 2004-12-30 2006-07-06 Agency For Science, Technology And Research Chinese hamster apoptosis-related genes
US20060263809A1 (en) * 2005-04-05 2006-11-23 The Rgents Of The University Of California Method for sensitive measure of low level apoptosis in cells
US20070092947A1 (en) * 2005-10-20 2007-04-26 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
WO2009012173A2 (en) * 2007-07-13 2009-01-22 Dharmacon, Inc. Enhanced biotherapeutic production using inhibitory rna
WO2009048024A1 (ja) * 2007-10-09 2009-04-16 Hiroshima University 目的遺伝子を染色体外で高度に増幅させるためのベクターおよびその利用
CN101952303A (zh) * 2008-02-25 2011-01-19 诺维信公司 提高目标蛋白质的表达产率的方法
US20100049284A1 (en) * 2008-05-15 2010-02-25 The Catholic University Of America Use of heat to treat biological systems exposed to damaging radiation
AU2009290563A1 (en) 2008-09-15 2010-03-18 Genentech, Inc. Compositions and methods for regulating cell osmolarity
BRPI0920572A8 (pt) 2008-10-20 2015-10-27 Abbott Lab Inativação viral durante a purificação dos anticorpos
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
JP2012518409A (ja) 2009-02-20 2012-08-16 ベントリア・バイオサイエンス タンパク質の組み合わせを含有する細胞培養培地
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
WO2014022102A1 (en) * 2012-08-01 2014-02-06 Amgen Inc. Methods of using anti-apoptotic compounds to modulate one or more properties of a cell culture
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
DE102013206438A1 (de) 2013-04-11 2014-10-16 Bühler Motor GmbH Permanentmagnetrotor für einen elektronisch kommutierten Gleichstrommotor
EP3049515B1 (de) 2013-09-23 2019-03-13 Wilson Wolf Manufacturing Corporation Verbesserte verfahren zur genetischen veränderung von tierzellen
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AU2015287760B2 (en) * 2014-07-09 2019-06-20 Genentech, Inc. pH adjustment to improve thaw recovery of cell banks
CA2981077A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
CN111349615B (zh) * 2018-12-24 2024-08-13 上海细胞治疗集团股份有限公司 制备过表达外源基因的细胞的方法
CN112080439B (zh) * 2020-07-30 2023-01-10 浙江工业大学 人源细胞凋亡调控蛋白Bcl-2在提高酿酒酵母橙花叔醇产量中的应用
US20230323422A1 (en) * 2020-08-14 2023-10-12 Bristol-Myers Squibb Company Method of making protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2971218B2 (ja) * 1991-12-04 1999-11-02 協和醗酵工業株式会社 ウリカーゼ遺伝子およびウリカーゼの製造法
GB9202796D0 (en) * 1992-02-11 1992-03-25 Wellcome Found Antiviral antibody
JPH09163983A (ja) * 1995-08-30 1997-06-24 Hisamitsu Pharmaceut Co Inc アポトーシス抑制による有用物質の効率的生産方法および細胞
FR2749021B1 (fr) 1996-05-23 2001-10-26 Agronomique Inst Nat Rech Lignees de cellules aviaires immortalisees
FR2749022B1 (fr) 1996-05-23 2001-06-01 Rhone Merieux Cellules aviaires immortelles
US5876923A (en) * 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
AU738048B2 (en) * 1996-09-12 2001-09-06 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors
US6072047A (en) * 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
ATE366803T1 (de) * 1999-09-08 2007-08-15 Genetrol Biotherapeutics Hohe zytokinproduktion mit verbesserte zelllebensfähigkeit
CA2384880C (en) * 1999-09-27 2010-09-21 Genentech, Inc. Methods for making recombinant proteins using apoptosis inhibitors

Also Published As

Publication number Publication date
ATE313634T1 (de) 2006-01-15
DE60025015D1 (de) 2006-01-26
DE60044690D1 (de) 2010-08-26
US20040002139A1 (en) 2004-01-01
WO2001023592A2 (en) 2001-04-05
IL148512A0 (en) 2002-09-12
EP1650307A2 (de) 2006-04-26
CA2384880C (en) 2010-09-21
PT1650307E (pt) 2010-10-21
DK1220934T3 (da) 2006-05-08
ES2346659T3 (es) 2010-10-19
EP1220934B1 (de) 2005-12-21
ES2254230T3 (es) 2006-06-16
IL148512A (en) 2011-04-28
WO2001023592A3 (en) 2001-12-20
HK1091228A1 (en) 2007-01-12
JP2003510087A (ja) 2003-03-18
US20100087624A1 (en) 2010-04-08
CA2384880A1 (en) 2001-04-05
EP1220934A2 (de) 2002-07-10
DE60025015T2 (de) 2006-08-03
EP1650307A3 (de) 2006-05-03
US20070004009A1 (en) 2007-01-04
AU7614600A (en) 2001-04-30
EP1650307B1 (de) 2010-07-14
US6586206B1 (en) 2003-07-01
DK1650307T3 (da) 2010-10-04

Similar Documents

Publication Publication Date Title
ATE313634T1 (de) Verfahren zur herstellung von rekombinanten proteinen mittels inhibitoren von apoptose
DE59608743D1 (de) Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte-fermentation
DE60238058D1 (de) Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau
DE60216959D1 (de) Sich in schlagende kardiomyozyten verwandelnde stammzellen
DE3888642D1 (de) Rollflasche zur Züchtung von Zellengewebekulturen.
WO2004096975A3 (en) Apparatus and methods for amplification of blood stem cell numbers
BR0214029A (pt) Métodos e composições para o uso de células estromais para suportar células tronco embriÈnicas e adultas
ATE250399T1 (de) Gebrauch von autologen, dermalen fibroblasten zur reperatur von haut- oder weichgewebeschäden
DK0917571T3 (da) Hidtil ukendt agoutirelateret gen
ATE430807T1 (de) Verfahren zur kultivierung von circovirus
DE502004008542D1 (de) Verfahren zur reklonierung von produktionszellen
BR8301918A (pt) Proteina,sequencia de dna,veiculo de expressao replicavel,microorganismo ou cultura celular,plasmideo,composicao,cultura de celulas,utilizacao de tal proteina,processo de expressao,processo para producao de um veiculo de expressao e processo para preparacao de uma proteina uroquinase
ATE79720T1 (de) Verfahren zur konservierung von transplantierbaren, in vitro kultivierten epithelgeweben.
DE69031656D1 (de) Saccharinderivate zur verwendung als proteolytische enzyminhibitoren sowie verfahren zur herstellung
DE60331871D1 (de) Pharmazeutische Verbindung und Methoden zur Behandlungen von menschliche Karzinome mittels Arginin Entzug
ATE309353T1 (de) Verfahren zur herstellung von rekombinanten peptiden
DE10390418D2 (de) Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
ATE421574T1 (de) Zellkulturmethode zur erzeugung von prostata- ähnlichen acini
DE69835813D1 (de) Verfahren zur kultivierung von zellen und zur vermehrung von viren
WO2002002591A3 (en) Peptides for use in culture media
DE60136558D1 (de) Verfahren zur kultivierung humaner chondrozyten
DE69916829D1 (de) Genetisch veränderte fibroblasten und ihre verwendung
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
DE59804251D1 (de) Verfahren zur gezielten herstellung von n-leitenden bereichen in diamantschichten mittels ionenimplantation
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1650307

Country of ref document: EP